Evidence map›Paper›PMID 38752363›Full record

ArticleNucleic acid therapeutics2024

Multiplexed

Brian J Thomas, Caitlyn Guldenpfennig, Mark A Daniels, Donald H Burke, David Porciani

Abstract read
In one paragraph

Article in Nucleic acid therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Brian J ThomasDepartment of Molecular Microbiology and Immunology, Bond Life Sciences Center, University of Missouri School of Medicine, Columbia, Missouri, USA.ORCID 0000-0002-0090-905X
Caitlyn GuldenpfennigDepartment of Molecular Microbiology and Immunology, Bond Life Sciences Center, University of Missouri School of Medicine, Columbia, Missouri, USA.ORCID 0000-0002-9633-0869
Mark A DanielsDepartment of Molecular Microbiology and Immunology, Bond Life Sciences Center, University of Missouri School of Medicine, Columbia, Missouri, USA.
Donald H BurkeDepartment of Molecular Microbiology and Immunology, Bond Life Sciences Center, University of Missouri School of Medicine, Columbia, Missouri, USA.
David PorcianiDepartment of Molecular Microbiology and Immunology, Bond Life Sciences Center, University of Missouri School of Medicine, Columbia, Missouri, USA.

Funding

Molecular engineering and systematic evaluation of bispecific aptamers to develop potent and efficacious therapies for the immunomodulation of Non-Small Cell Lung CancerF30CA275349 · NCI · UNIVERSITY OF MISSOURI-COLUMBIA · PI Brian J Thomas · 2023 to 2026
$187k
NCI NIH HHS F30 CA275349
6 · The paper itself

Abstract

Recent FDA approvals of mRNA vaccines, short-interfering RNAs, and antisense oligonucleotides highlight the success of oligonucleotides as therapeutics. Aptamers are excellent affinity reagents that can selectively label protein biomarkers, but their clinical application has lagged. When formulating a given aptamer for

Indexed as

Aptamers, NucleotideAnimalsCarcinoma, Non-Small-Cell LungCell Line, TumorHumansLung NeoplasmsMiceOligonucleotidesSELEX Aptamer TechniqueXenograft Model Antitumor AssaysAptamers, NucleotideOligonucleotidesbiodistributionHTSlung cancernext-generation amplicon sequencingoligonucleotide therapeutics and diagnosticstumor targeting

Identifiers

PMID38752363
PMCPMC11250842

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.